Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on May 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Saira Ramasastry resigns as director and Audit Committee Chair effective May 26, 2026.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Saira Ramasastry resigns as director and Audit Committee Chair effective May 26, 2026
- Departure attributed to a business conflict, not disagreement with Vir’s operations or policies
- Robert More appointed Audit Committee Chair effective May 26, 2026
- Board reduced from eight to seven members, lowering director oversight capacity
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected Robert More, Janet Napolitano, and Elliott Sigal to Class I director terms through 2029
- Janet Napolitano faced the weakest support, with 67,235,175 votes for versus 54,454,756 withheld
- Executive compensation received advisory approval, with 108,453,963 votes for and 11,863,405 against
- Ernst & Young LLP ratified as 2026 independent auditor, with 137,048,756 votes for and 153,836 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.